PATIENT IMPACT STATEMENT

In February 2022, the coalition released its first Joint Patient Impact Statement which focused on recommendations for governments and health authorities and was developed for use in different countries to aid when advocating for the provision of anti-COVID-19 treatment and care for immunocompromised (IC) blood cancer patients. Following on from this previous version,  end of May 2023 the coalition released a revised statement. This latest version of the ICBCC Joint Patient Impact Statement discusses helping patients help themselves so they can re-engage with the world.

The Statement has been endorsed by more than 70 researchers, clinicians, patient organisations and medical societies.